Boris Klebanov - Concepedia

Author

Boris Klebanov

Karyopharm Therapeutics (United States)ORCID

Also Known As

B Klebanov, B M Klebanov, B. Klebanov, B. M. KLEBANOV, B. M. Klebanov, B.M. Klebanov, Boris Klebanov, Boris M. Klebanov, Klebanov, Boris

111

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

Karyopharm Therapeutics (United States)Harvard University University of Toronto The Ohio State University Princess Margaret Cancer Centre

About

Boris Klebanov is an author at Karyopharm Therapeutics (United States) specializing in medicine, cell biology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	726
2	Engineering	2	2	738
3	Natural Sciences	2	2	82
4	Biochemistry	1	1	12
5	Biomedical Engineering	1	1	603

Boris Klebanov

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity Kathryn A. Whitehead, J. Robert Dorkin, Arturo J. Vegas, Nature Communications NanoparticlesNanomedicineEngineeringDegradable Lipid NanoparticlesTherapeutic Nanomaterials	2014	603
In Vivo Silencing of the Transcription Factor IRF5 Reprograms the Macrophage Phenotype and Improves Infarct Healing Gabriel Courties, Timo Heidt, Matthew Sebas, Journal of the American College of Cardiology InflammationThrombopoiesisTranscriptional RegulationSignaling PathwayImmunology	2013	277
Cutting Edge: Hypoxia-Inducible Factor 1α and Its Activation-Inducible Short Isoform I.1 Negatively Regulate Functions of CD4+ and CD8+ T Lymphocytes Dmitriy Lukashev, Boris Klebanov, Hidefumi Kojima, The Journal of Immunology	2006	204
Influence of Cationic Lipid Composition on Gene Silencing Properties of Lipid Nanoparticle Formulations of siRNA in Antigen-Presenting Cells Genc Basha, Tatiana I. Novobrantseva, Nicole L. Rosin, Molecular Therapy	2011	176
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia Ramiro Garzon, Michael R. Savona, Rachid Baz, Blood	2017	147
Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells Tatiana I. Novobrantseva, Anna Borodovsky, Jamie Wong, Molecular Therapy — Nucleic Acids NanotherapeuticsEngineeringGeneticsImmunologyImmunotherapeutics	2012	135
Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death Trinayan Kashyap, Christian Argueta, Amro Aboukameel, Oncotarget Proteasome InhibitorsChemoprevention StrategyImmunologyCell DeathCancer Biology	2016	125
Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice Julia Etchin, Joan Montero, Alla Berezovskaya, Leukemia Nuclear ExportCell TherapySignal TransductionAml-initiating CellsMedicine	2015	81
Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis Kellie R. Machlus, Stephen Wu, Prakrith Vijey, Blood	2017	71
New fluorine-containing hypotensive preparations L. M. YAGUPOL'SKII, I. I. MALETINA, Dmitrij V. Fedyuk, Journal of Fluorine Chemistry HalogenationMedicinal ChemistryNatural SciencesFluorous SynthesisOrganic Chemistry	2001	70

Page 1